Current NDC auxiliary source row compounder:146

This page is keyed by dataset, FDA.report source record ID, and physical source row number. Empty values are shown rather than omitted.

Complete normalized row#

Record Source: ndc_compounder_zip
Product Ndc Raw: 26436-5311
Product Ndc: 26436-5311
Product Ndc Digits: 264365311
Product Type Name: HUMAN COMPOUNDED DRUG
Proprietary Name: LET Topical Gel
Proprietary Name Suffix: [empty]
Nonproprietary Name: LET Topical Gel
Dosage Form Name: GEL
Route Name: TOPICAL
Marketing Category Name: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
Labeler Name: Hybrid Pharma
Establishment Name: Hybrid Pharma
Establishment Fei: [empty]
Substance Name: EPINEPHRINE; TETRACAINE; LIDOCAINE HYDROCHLORIDE
Active Ingredients Info: .5 mg/1 mL; 5 mg/1 mL; 40 mg/1 mL
History Active Ingredients Raw: EPINEPHRINE; TETRACAINE; LIDOCAINE HYDROCHLORIDE
History Active Ingredients Info Raw: .5 mg/1 mL; 5 mg/1 mL; 40 mg/1 mL
History Dosage Raw: GEL
Dea Schedule: [empty]
Package Ndc Raw: 26436-5311-1
Package Ndc: 26436-5311-1
Package Ndc Digits: 2643653111
Package Ndc11: 26436531101
Package Description: 3 mL in 1 SYRINGE (26436-5311-1)
Reporting Period Raw: 2025-1
Reporting Period: 2025-1
Normalization Status: valid
Source Url: https://www.accessdata.fda.gov/cder/compounders_ndc_directory.zip
Source Archive: compounders_ndc_directory.zip
Source File: compounders_ndc_directory.txt
Source Date: 2026-09-18
Source Last Modified: Fri, 18 Sep 2026 15:17:23 GMT
Source Archive Sha256: 222f6800f79cb1a0fa79431b7226bd6b34899999dbf086af51004a96774ada98
Source Member Sha256: f8d9743e5616579a34d614887e86a53913efa0a63d3138d59d2f87cbb4d0cc17
Source Record Id: compounder:146
Source Row Number: 146
Source Row Hash: 6149f548428454af47c135ee93a177c494977fe617551390339646023b636a4b
Import Run Id: 20261018T022251Z
Loaded At: 2026-10-18 02:29:51

Exact raw FDA source fields#

{
    "ROUTENAME": "TOPICAL",
    "PRODUCTNDC": "26436-5311",
    "DEASCHEDULE": "",
    "LABELERNAME": "Hybrid Pharma",
    "SUBSTANCENAME": "EPINEPHRINE; TETRACAINE; LIDOCAINE HYDROCHLORIDE",
    "DOSAGEFORMNAME": "GEL",
    "NDCPACKAGECODE": "26436-5311-1",
    "PRODUCTTYPENAME": "HUMAN COMPOUNDED DRUG",
    "PROPRIETARYNAME": "LET Topical Gel",
    "REPORTINGPERIOD": "2025-1",
    "NONPROPRIETARYNAME": "LET Topical Gel",
    "PACKAGEDESCRIPTION": "3 mL in 1 SYRINGE (26436-5311-1) ",
    "ACTIVEINGREDIENTSINFO": ".5 mg/1 mL; 5 mg/1 mL; 40 mg/1 mL",
    "MARKETINGCATEGORYNAME": "OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)",
    "PROPRIETARYNAMESUFFIX": ""
}

Normalization notes#

[]

Current status projection#

Dataset: compounder
Record Source: ndc_compounder_zip
Source Record Id: compounder:146
Source Row Number: 146
Status Scope: package
Lookup Ndc: 26436-5311-1
Lookup Ndc Digits: 2643653111
Product Ndc: 26436-5311
Product Ndc Digits: 264365311
Package Ndc: 26436-5311-1
Package Ndc Digits: 2643653111
Package Ndc11: 26436531101
Product Id: [empty]
Status Code: COMPOUNDER
Status Label: Outsourcing facility compounded drug report
Reporting Period Raw: 2025-1
Reporting Period: 2025-1
Source Table: fda_ndc_aux_compounder
Source File: compounders_ndc_directory.txt
Source Date: 2026-09-18
Source Row Hash: 6149f548428454af47c135ee93a177c494977fe617551390339646023b636a4b
Import Run Id: 20261018T022251Z
Loaded At: 2026-10-18 02:29:51